For prostate cancer, core fucosylation of prostate specific antigen (PSA) has been widely investigated as a biomarker for aggressive disease [51, 52, 53, 54, 55] and serum fucosylated haptoglobin is known to be upregulated in high grade disease [56]. Here, KLK3 is linked to prostate cancer.